Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients
Authors:
- 11 May 2017
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 19 (10) , 1283-1291
Abstract
Purpose Non-invasive methods of molecular profiling for non-small cell lung cancer (NSCLC) are useful for monitoring disease progression. The aim of the current study was to ascertain if transrenal DNA is sensitive for clinical correlation and EGFR detection in NSCLC patients. Methods 160 patients at various stages of the disease participated and samples were collected prospectively at 2-month intervals. A baseline sample was taken before treatment commencement. To ascertain the sensitivity of transrenal DNA, we compared its results with plasma DNA. ddPCR was used to profile the urine and blood samples for key EGFR mutations. Results Using tumor tissues as references, our study showed good concordance in EGFR mutations with transrenal DNA before treatment. Results were highly matching in late-stage NSCLC patients, with stage III/IV patients yielding an agreement of more than 90%. The assay was also sensitive to detect early-stage patients after surgical procedures. Profiles were highly concordant with results derived from plasma DNA, demonstrating the specificity of transrenal DNA assays. Serial monitoring of these patients showed stable molecular signatures and correlated to different treatments. Survival analysis showed good prognostic utility for late-stage patients with high transrenal DNA variations and patients that acquired T790M mutation. Conclusion The study demonstrated the feasibility of using transrenal DNA in mutation profiling for different stages of NSCLC patients. It highlights the importance of continual monitoring and has potential clinical utility in the clinical management of NSCLC.Keywords
Funding Information
- Wuhan No. 6 Hospital, Affiliated Hospital to Jianghan University
This publication has 31 references indexed in Scilit:
- Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the diseaseSpringerPlus, 2016
- Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patientsCancer Letters, 2016
- Liquid Biopsies: Genotyping Circulating Tumor DNAJournal of Clinical Oncology, 2014
- Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future TherapiesJournal of Clinical Oncology, 2013
- Metabolomics of urinary tract infection: a new uroscope in townExpert Review of Molecular Diagnostics, 2012
- Origin and quantification of circulating DNA in mice with human colorectal cancer xenograftsNucleic Acids Research, 2010
- Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)Journal of Clinical Oncology, 2009
- Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic PathwaysScience, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Human Urine Contains Small, 150 to 250 Nucleotide-Sized, Soluble DNA Derived from the Circulation and May Be Useful in the Detection of Colorectal CancerThe Journal of Molecular Diagnostics, 2004